Related Experiment Videos
Evidence-based medicine for apheresis: an ongoing challenge
1Department of Transfusion Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5283, USA. lmmcarth@iupui.edu
Summary
Plasma exchange is a key treatment for thrombotic thrombocytopenic purpura (TTP). Solvent detergent plasma minimizes allergic reactions, and recombinant ADAMTS-13 shows promise for diagnosis and treatment of TTP.
Area of Science:
- Hematology
- Internal Medicine
Background:
- Thrombotic thrombocytopenic purpura (TTP) remains a challenging condition with problematic etiology and treatment options.
- Despite advances since its initial description, effective management strategies for TTP are still evolving.
Purpose of the Study:
- To review the experience with plasma exchange in treating over 160 patients with TTP.
- To evaluate different plasma exchange media, including fresh frozen plasma (FFP), solvent detergent (SD) plasma, and cryopoor plasma.
- To discuss the role of splenectomy and the potential of recombinant ADAMTS-13 in TTP management.
Main Methods:
- Plasma exchange was utilized as a primary treatment modality for TTP patients.
- Comparison of allergic reactions associated with different plasma exchange media (FFP, SD plasma, cryopoor plasma).
- Review of historical treatment options (splenectomy) and emerging therapies (recombinant ADAMTS-13).
Main Results:
- Plasma exchange has been a cornerstone in managing TTP since 1975.
- Solvent detergent (SD) plasma significantly reduces or eliminates allergic reactions during treatment.
- Splenectomy remains a viable option for refractory TTP cases.
Conclusions:
- Plasma exchange, particularly with SD plasma, offers an improved safety profile for TTP treatment.
- Recombinant ADAMTS-13 holds potential for enhanced diagnostics and targeted therapies for both acquired and familial TTP.
- Continued research into TTP pathophysiology and treatment is crucial for better patient outcomes.